|
WO2016072452A1
|
|
Phytosphingosine derivative having sulfonyl group
|
|
WO2016031742A1
|
|
Ameliorating agent for paresthesia induced by peripheral nerve disorders
|
|
WO2015182749A1
|
|
TCR cDNA AMPLIFICATION METHOD
|
|
WO2015098928A1
|
|
Inhibitor of il-1 and tnf activities
|
|
WO2015056727A1
|
|
Medium for improving development rate of fertilized eggs having low conception rate
|
|
WO2015016293A1
|
|
(benzenesulfonylamino)benzamide derivative, and ship2 inhibitor containing same as active ingredient
|
|
WO2014132936A1
|
|
Method for selectively amplifying placental or periplacental tissue stem cells
|
|
WO2014129437A1
|
|
Mental disorder inspection method and inspection kit
|
|
WO2014123231A1
|
|
Method of identifying t-cell receptor antigen, and reporter cells for identification
|
|
WO2015052776A1
|
|
Aluminum alloy for cast production and casting using same
|
|
WO2014014077A1
|
|
Method for detecting drug resistance mutation in cytomegalovirus, and method for identifying drug resistance mutation gene
|
|
WO2013146696A1
|
|
Intravascular injection monitoring device and intravascular injection monitoring system using same
|
|
KR20150000875A
|
|
Serine racemase inhibitor
|
|
WO2013073454A2
|
|
Controlled release composition for physiologically active substance
|
|
TW201415026A
|
|
Apparatus for the treatment of palstics material
|
|
WO2013035794A1
|
|
Wave-absorbing structure
|
|
WO2013022080A1
|
|
Method for assessing numbness or spontaneous pain using animal
|
|
WO2012169571A1
|
|
Novel n-(pyridin-2-yl)alkanamide derivative and ship2 inhibitor containing same as an active ingredient
|
|
WO2012157744A1
|
|
1-THIOXO-1,2,3,4-TETRAHYDRO-β-CARBOLINE DERIVATIVE AND ANTI-CANCER AGENT COMPRISING SAME
|
|
WO2012060347A1
|
|
Organic hybrid type catalyst
|
